Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice-daily version of the drug late last year.The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lillyand Novo Nordisk that will offer patients a more convenient alternative to injections.Some analysts expect the weight-loss drug market, currently dominated by Novo Nordisk’s ...

Key TakeawaysPfizer shares rose as the company said it would be moving forward with studies of a once-a-day oral weight-loss pill after testing its modified release formulation.The pill has the same GLP-1 receptor agonists used in the injectable obesity treatments from Novo Nordisk and Eli Lilly.Pfizer reported the drug was successful when given twice a day, but caused adverse side effects. Shares of Pfizer (PFE) advanced as the drug maker announced that it was moving forward with research into a potential ...

On Thursday, Pfizer announced plans to advance its weight-loss pill after "encouraging" results from an early-stage study.  The pharmaceutical giant is trying to tap into the highly lucrative market for obesity drugs currently dominated by the likes of Eli Lilly and Novo Nordisk. HIMS & HERS ROLLS OUT WEIGHT-LOSS SHOTS MUCH CHEAPER THAN OZEMPIC, WEGOVY Pfizer said it has a "robust pipeline" of three clinical and several other pre-clinical candidates but that danuglipron, a once-a-day oral treatment, was "th ...

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images)NurPhoto via Getty ImagesWe believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, versus 23.5x for LLY, and we think this gap in valuation will remain wide in favor of Eli Lilly. There is more to the compariso ...

ProArtWork Pfizer's (NYSE:PFE) cash flow from operations in 2022, driven by sales of the company's COVID-19 vaccine and Paxlovid, hit $29.267 billion. Fast-forward to 2023, and with COVID largely behind us, revenue from those products plummeted, pushing cash flow from operations down to $8.7 billion. With that in mind, it's not difficult to understand why the stock fell by roughly 23% over the last year. But there is more to Pfizer than coronavirus meds. The firm has a solid drug pipeline, and in an industr ...

Pfizer (PFE) closed the latest trading day at $27.93, indicating a -0.43% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.1%. At the same time, the Dow lost 0.08%, and the tech-heavy Nasdaq gained 0.28%.Prior to today's trading, shares of the drugmaker had lost 1.85% over the past month. This has lagged the Medical sector's loss of 0.44% and the S&P 500's gain of 4.08% in that time.Analysts and investors alike will be keeping a close eye on the perfo ...

Don't ignore this drugmaker simply because it's been unable to come up with a full replacement for Lipitor.Pfizer (PFE -0.20%) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has it paid a dividend like clockwork for decades, the company has regularly raised its annual payout in recent years. Now that the dividend is well established, this streak isn't apt to end in the foreseeable ...

Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices.The past few years have been tough ones for investors holding shares of Pfizer (PFE 1.26%). The Big Pharma stock is down by more than half from the peak it set in late 2021.Pfizer's stock price was hammered, but that didn't prevent the company from meeting and raising its dividend commitment. Last December, the pharmaceutical company raised its payout for the 15th consecutive year.Shares of Pfizer offer an eye-popping 6 ...

文章核心观点 - 辉瑞公司正在努力进入由Ozempic和Wegovy等GLP-1药物主导的减肥治疗领域[1][2] - 辉瑞之前的GLP-1候选药物lotiglipron和danuglipron均因安全性问题而被迫停止临床试验[3][4] - 辉瑞CEO表示公司正在研发3种减肥药物,包括2种GLP-1机制和1种非GLP-1机制的药物[5][6] - 辉瑞股价呈现下降三角形走势,面临一些下行压力[7] 公司业务表现 - 辉瑞正在努力从COVID-19疫苗和治疗药物收入下降的影响中恢复[9][10] - 公司Q1 2024财报显示收入同比下降19.5%,但非COVID-19业务收入增长11%[10] - 公司预计2024年全年收入将达585亿美元至615亿美元,调整后每股收益为2.15美元至2.35美元[11] - 公司CEO对非COVID-19业务表现持乐观态度,多个主要产品线如Eliquis、Prevnar和Vyndaqel等实现了良好增长[12][13] 行业竞争格局 - 除了Novo Nordisk和Eli Lilly,辉瑞还面临来自Viking Therapeutics、Altimmune和Structure Therapeutics等其他GLP-1药物开发商的竞争[2] - 辉瑞之前的GLP-1候选药物lotiglipron和danuglipron均因安全性问题而被迫停止临床试验,未能成为有力的竞争对手[3][4] - 辉瑞正在研发新的减肥药物,希望能在这一领域分一杯羹[5][6]

Pfizer's valuation looks attractive, but that doesn't mean the stock is a lock to outperform the broader market. Pfizer (PFE 0.86%) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess a lot of upside in the long run. Investors, however, aren't exactly loading up on the stock. Year to date, it's down around 3%. The shares' ...